Twitter | Search | |
Search Refresh
Parneet Cheema May 22
Many recent advances in the treatment of advanced EGFR-mutated lung cancer. We reviewed the data & developed a new 🇨🇦systemic treatment algorithm
Reply Retweet Like
JTO 22h
JTO Research Watch: "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant ."
Reply Retweet Like
Stephen V Liu May 22
Brigatinib receives approval from the for the first line treatment of positive . Based on the phase III ALTA-1L trial which compared brigatinib to crizotinib and showed PFS HR 0.49, ORR 74% and intracranial RR 78%.
Reply Retweet Like
BTOG May 21
Join BTOG Steering Committee members for an update on relevant data/research from on advanced stage : & targeted therapies, locally advanced NSCLC, and . Register for our webinar 'ASCO In an Hour'
Reply Retweet Like
giovanni selvaggi, MD May 22
Another option for positive patients ! Outstanding effort from to support the community and the search for a cure.
Reply Retweet Like
Laura Mezquita 14h
The identification 🔬 of resistance mechanisms to MET-TKI will help to optimize the sequential therapies 💊 and the overall therapeutic strategy for our pts 🔝🔝😊 AMAZING work
Reply Retweet Like
Inivata May 20
Join our next Virtual Tumor Board on tomorrow at noon, powered by Dr. Edgardo Santos will be moderating this session. Remember that you can submit your cases for discussion. Register here:
Reply Retweet Like
Oriol Mirallas MD May 23
New potential target for and ⏩ ROR1 & MUC1 ✅ Great talk by Dr.Specht about first results of ROR1 CAR T cells
Reply Retweet Like
Daiichi Sankyo US May 18
Thrilled to share that our investigational treatment received Breakthrough Therapy Designation for treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation.
Reply Retweet Like
Martijn A. Spruit 4h
Approximately 30% of patients with stage I have a clinically significant decrease in QOL one year after stereotactic body radiotherapy or surgical resection.
Reply Retweet Like
Gil Morgan May 22
Just Out📣 🇺🇸approves brigatinib💊as a1️⃣st Line Treatment Option in adults with ALK➕🧬metastatic non-small cell ‼️ Approval is based on results from the Phase3️⃣ALTA 1L trial 🚨 ’s-ALUNBRIG®-brigatinib-First-Line
Reply Retweet Like
Gil Morgan May 18
Just Out📣 🇺🇸Grants Breakthrough Designation to Trastuzumab Deruxtecan🧪for HER2+🧬metastatic who progressed on platinum ‼️ Based on II DESTINY-Lung01 trial LCSM via
Reply Retweet Like
Daiichi Sankyo US May 21
About 80-85 percent of all lung cancers are non-small cell lung cancer or NSCLC. HER2 mutations occur in approximately 2-4 percent of .
Reply Retweet Like
Apollomics May 21
We are excited to announce the initiation of our Phase 2 SPARTA trial for our c-MET Inhibitor APL-101
Reply Retweet Like
Charu Aggarwal, MD, MPH May 22
starts in 1 Wk, new data on , activity of amivantamab, osimertinib & poziotinib in , ORR~25% for both TKIs, slightly higher ~36% w/ amivantamab. Look fwd to an engaging poster discussion by
Reply Retweet Like
Stephen V Liu May 18
FDA approval of 1L atezolizumab (anti-PD-L1) as monotherapy for PDL1 high . Based on IMpower 110 which showed an OS HR of 0.59 in PDL1 high versus chemotherapy). Good to have more options and sets the stage for more combos.
Reply Retweet Like
Joseph Shatzel May 16
ALK rearrangements conferred a 4-fold increase in VTE risk and 3-fold increase in arterial thrombosis risk in NSCLC. Fascinating work from my friend Hanny and
Reply Retweet Like
ASCO Publications May 21
Reply Retweet Like
Univadis UK May 23
Open-label study has shown that improves PFS and OS compared to platinum doublet chemotherapy or ABCP in patients with ALK-positive advanced . The recommended dose is 100 mg taken orally once per day.
Reply Retweet Like
Tyler McCurry May 21
Can’t miss webinar! Wed, June 3rd @ 7PM EST. Dr. Bobby Mahajan - Interventional Pulmonologist and - Thoracic Oncologist discuss drawing NGS Plasma at time of Lung Biopsy! Click here to register
Reply Retweet Like